Why the study?
Preclinical and early human trials suggest FXIa inhibition prevents VTE and alleviates cytokine storm, supporting roles for FXI beyond coagulation that warranted exploration.
Population
Patients with acute VTE (n = 549) and at 12 months after (n = 187)
Comparison
Plasma protein profiling associated with varying FXI:C levels
Design
Observational cohort study using targeted proteomics and bioinformatics
Follow-up
12-months
Authors
Loading...
FXI:C-protein associations in VTE are hypothesis-generating; leaves open whether FXIa inhibition modulates inflammation or outcomes beyond anticoagulation.
FXI activity is associated with plasma proteins enriched in immune pathways related to thrombo-inflammation, extracellular matrix interaction, lipid metabolism, and apoptosis in patients with VTE.
Robles et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: